November 2017 Vol 10, No 8

"Opioids Equal Heroin"

David B. Nash, MD, MBA

November 2017 Vol 10, No 8 - Editorial

Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor

JoAnne Foody, MD, Robin S. Turpin, PhD, Beni A. Tidwell, BS, Debra Lawrence, PhD, Kathy L. Schulman, MS

November 2017 Vol 10, No 8 - Clinical, Original Research

Stakeholder Perspective

The Growing Role of Real-World Evidence in Clinical Decision-Making

by Gary M. Owens, MD

Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors

Rajeev Ayyagari, PhD, Maureen Neary, PhD, MS, Shang Li, MS, Ariel Rokito, BS, Hongbo Yang, PhD, Jipan Xie, MD, PhD, Al B. Benson III, MD, FACP, FASCO

November 2017 Vol 10, No 8 - Business, Original Research

The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers

Peter R. Fendt, PharmD, MBA, Brian Ung, PharmD, RPh, F. Randy Vogenberg, PhD

November 2017 Vol 10, No 8 - Industry Trends

Results 1 - 4 of 4